Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
- About
Savara Inc(SVRA)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for SVRA
09/14/2026: SVRA (1-star) is currently NOT-A-BUY. Pass it for now.
Savara Inc is a clinical-stage biotechnology company developing inhaled therapies for rare respiratory conditions like pulmonary alveolar proteinosis. Its primary value rests on the clinical progression of its lead candidate, molgramostim, which has received orphan drug designation. The company's main strength is its specialized focus, though it faces high risks typical of early-stage biotech, including binary outcomes from clinical trials and the need for ongoing financing. Investors should monitor clinical data readouts and regulatory engagement, as these are the primary catalysts for long-term growth. The stock is best suited for growth-oriented investors with a high risk tolerance and a focus on biotech innovation.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers high growth potential linked to clinical success but entails high binary risk. |
| Momentum investor | Strong fit while signal remains positive | Momentum investors may find entry points based on clinical trial milestones and regulatory news flow. |
| Value investor | Weak fit | The lack of current earnings or dividends makes it unsuitable for traditional value-based strategies. |
| Dividend investor | Weak fit | Savara provides no income and reinvests all capital into R&D. |
| Low-risk investor | Weak fit | The binary nature of drug development makes this stock unsuitable for conservative portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical-stage biotech stocks often experience significant price swings based on trial results. |
| Valuation risk | Medium / high | Valuations are heavily dependent on future probability-weighted success of drug candidates. |
| Competition risk (Rare respiratory therapy) | Medium | Larger companies with more resources may develop competing treatments or diagnostic tools. |
| Business quality | Medium | The company is reliant on the successful development of a single lead asset. |
| Dividend income | Low / none | No dividend income is expected for the foreseeable future. |
| Execution risk | High | The company must successfully navigate complex regulatory and commercialization hurdles. |
Price Behavior
Downtrend
The stock has experienced a sustained decline in price over recent periods.
Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit -5.8% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/14/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.09B USD | Price to earnings Ratio - | 1Y Target Price 10.94 |
Price to earnings Ratio - | 1Y Target Price 10.94 | ||
Volume (30-day avg) 1.5M shares | Beta 0.25 | 52 Weeks Range 3.34 - 7.00 | Updated Date 09/13/2026 |
52 Weeks Range 3.34 - 7.00 | Updated Date 09/13/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.58 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Clinical-Stage R&D | Development of molgramostim and potential future rare respiratory assets. | The company currently makes no money and is investing capital to reach regulatory approval for its drugs. |
Valuation
Trailing PE - | Forward PE 0.41 | Enterprise Value 947.34M | Price to Sales(TTM) 145272.62 |
Enterprise Value 947.34M | Price to Sales(TTM) 145272.62 | ||
Enterprise Value to Revenue 4269.22 | Enterprise Value to EBITDA -4.76 | Shares Outstanding 204.93M | Shares Floating 129.69M |
Shares Outstanding 204.93M | Shares Floating 129.69M | ||
Percent Insiders 2.59 | Percent Institutions 106.66 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Savara Inc
Exchange NASDAQ | Headquarters Yardley, PA, United States | ||
IPO Launch date 2017-06-01 | Chairman & CEO Mr. Matthew Pauls J.D., M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 70 | Website https://www.savarapharma.com |
Full time employees 70 | Website https://www.savarapharma.com | ||
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Yardley, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.